Ceritinib kann auch bei Hirnmetastasen effektiv sein

September 2017, Volume 20, Issue 5, pp 12–14 | Cite as

ALK-positives NSCLC

journal club

First Online: 02 September 2017

Schlüsselwörter

Ceritinib NSCLC ALK-Inhibitor Hirnmetastasen

This is a preview of subscription content, to check access.

1.
Shaw AT et al. Lancet Oncol. 2017;18(7):874-86.CrossRefPubMedGoogle Scholar
2.
Costa DN. Lancet Oncol. 2017 Jun 8. [Epub ahead of print].Google Scholar
3.
Lockney NA, Wu AJ. J Thorac Dis. 2017;9(2):E152-E154.CrossRefPubMedPubMedCentralGoogle Scholar
4.
Shepherd FA et al. J Clin Oncol. 2000;18(10):2095-103.CrossRefPubMedGoogle Scholar

Shaw AT et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18(7):874-86.CrossRefPubMedGoogle Scholar